tbuckley/cabot-search huggingface dataset:
Main Characteristics of Zika Virus Exanthema in Guadeloupe
Authors: Nadège Cordel, Xavier Birembaux, Hugo Chaumont, Frédérique Delion, Olivier Chosidow, Benoit Tressières, Cécile Herrmann Storck
Journal: JAMA Dermatology (2017)

Clinical characteristics of Dengue and Chikungunya virus exanthema****** -Dengue: non pruritic macular exanthema located on trunk and limbs including palms and or soles with frequent hemorrhagic signs (petechiae, purpura) associated with high grade fever and flu-like symptoms.-Chikungunya : non pruritic generalized maculopapular exanthema associated with high grade fever and acute incapacitating arthralgia.*missing data for one adult ** missing data for 3 adults and 3 children, patients (adults n=2; children n=1) with ascending and descending exanthema not taken into account *** missing data for one child **** missing data for 4 patients( 2 adults, 1 child) ***** missing data for 4 patients( 1 adults, 3 children) **
A Prognostic Model for Predicting the Impact of Comorbidities on Survival of Patients with Myelodysplastic Syndromes.
Authors: Matteo G. Della Porta, Luca Malcovati, Erica Travaglino, Cristiana Pascutto, Margherita Maffioli, Rosangela Invernizzi, Mario Cazzola
Journal: Blood (2007)
Evaluation of panitumumab (PMAB) plus folfiri versus folfiri alone as second-line therapy in patients (PTS) with metastatic colorectal cancer (MCRC) receiving prior bevacizumab (BEV) in study 20050181
Authors: Marc Peeters, Timothy Price, Andrew Strickland, Tudor-Eliade Ciuleanu, Werner Scheithauer, Seamus O'Reilly, Maccon Keane, David Spigel, Ying Tian, Kartik Krishnan
Journal: Annals of Oncology (2011)
Factors That Determine Overall Survival among Patients (Pts) with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZOL): Lack of Skeletal-Related Events (SREs) and Occurrence of Osteonecrosis of the Jaw (ONJ) Predict Improved Survival.
Authors: James R. Berenson, Ori Yellin, John Crowley, Herbert Duvivier, Youram Nassir, Regina A. Swift
Journal: Blood (2007)
Targeted Sequencing for Clinical Investigation in Chronic Lymphocytic Leukemia
Authors: Damien Roos-Weil, Jérôme Lambert, Nathalie M. Droin, Frederik Damm, Romain Guieze, M'boypa Diop, Pierre Feugier, Stéphane Leprêtre, Xavier Troussard, Vincent Ribrag, Sandrine Vaudaux, Roselyne Delepine, Sophie Raynaud, Julie Lejeune, Claude Lesty, Olivier A. Bernard, Florence Nguyen-Khac
Journal: Blood (2016)
Association of a Community Campaign for Better Beverage Choices With Beverage Purchases From Supermarkets
Authors: Marlene B. Schwartz, Glenn E. Schneider, Yoon-Young Choi, Xun Li, Jennifer Harris, Tatiana Andreyeva, Maia Hyary, Nicolette Highsmith Vernick, Lawrence J. Appel
Journal: JAMA Internal Medicine (2017)

Data are needed to evaluate community interventions to reduce consumption of sugary drinks. Supermarket sales data can be used for this purpose.To compare beverage sales in Howard County, Maryland (HC), with sales in comparison stores in a contiguous state before and during a 3-year campaign to reduce consumption of sugary beverages.This observational experiment with a control group included 15 HC supermarkets and 17 comparison supermarkets. Weekly beverage sales data at baseline (January 1 to December 31, 2012) and from campaign years 1 to 3 (January 1, 2013, through December 31, 2015) were analyzed. A difference-in-differences (DID) regression compared the volume sales per product per week in the HC and comparison stores, controlling for mean product price, competitor's product price, product size, weekly local temperature, and manufacturer.The campaign message was to reduce consumption of all sugary drinks. Television advertising, digital marketing, direct mail, outdoor advertising, social media, and earned media during the 3-year period created 17 million impressions. Community partners successfully advocated for public policies to encourage healthy beverage consumption in schools, child care, health care, and government settings.Sales were tracked of sugary drinks highlighted in the campaign, including regular soda, sports drinks, and fruit drinks. Sales of diet soda and 100% juice were also tracked. Sales data are expressed as mean fluid ounces sold per product, per store, per week.Regular soda sales in the 15 HC supermarkets decreased (-19.7%) from 2012 through 2015, whereas sales remained stable (0.8%) in the 17 comparison supermarkets (DID adjusted mean, -369 fl oz; 95% CI, -469 to -269 fl oz; P < .01). Fruit drink sales decreased (-15.3%) in HC stores and remained stable (-0.6%) in comparison stores (DID adjusted mean, -342 fl oz; 95% CI, -466 to -220 fl oz; P < .001). Sales of 100% juice decreased more in HC (-15.0%) than comparison (-2.1%) stores (DID mean, -576 fl oz; 95% CI, -776 to -375 fl oz; P < .001). Sales of sports drinks (-86.3 fl oz; 95% CI, -343.6 to 170.9 fl oz) and diet soda (-17.8 in HC stores vs -11.3 in comparison stores; DID adjusted mean, -78.9 fl oz; 95% CI, -182.1 to 24.4 fl oz) decreased in both communities, but the decreases were not significantly different between groups.A locally designed, multicomponent campaign to reduce consumption of sugary drinks was associated with an accelerated decrease in sales of regular soda, fruit drinks, and 100% juice. This policy-focused campaign provides a road map for other communities to reduce consumption of sugary drinks.
Higher Hematopoietic Cell Transplant Comorbidity Index (HCT-CI) Is Associated with Poor Psychosocial Health Pre-Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients
Authors: Pradnya D Patil, Lisa Rybicki, Donna Abounader, Hien K. Liu, Brian T. Hill, Robert Dean, Betty K. Hamilton, Aaron T. Gerds, Brad Pohlman, Ronald Sobecks, Brian J. Bolwell, Matt Kalaycio, Navneet S. Majhail, Deepa Jagadeesh
Journal: Blood (2016)
Correlation Between Imatinib Trough Concentration and Long-Term Tolerability in CML Patients
Authors: Masayoshi Masuko, Tatsuo Furukawa, Toyoyuki Tanaka, Syukuko Miyakoshi, Takashi Kozakai, Kyoko Fuse, Yasuhiko Shibasaki, Kazue Takai, Yoshinobu Seki, Masashi Kobayashi, Koichi Nagai, Hoyu Takahashi, Kenji Kishi, Miwako Narita, Masuhiro Takahashi, Tadashi Koike, Akira Shibata
Journal: Blood (2012)
Primary Care Referrals for Suspected Hematologic Malignancies: Incidence, Factors Affecting Choice of Specialist, and Flow of Referral Information.
Authors: Gregory A. Abel, Christopher R. Friese, Bridget A. Neville, Lisa C. Richardson, Katherine M. Wilson, B. Taylor Hastings, Craig C. Earle, Robert J. Soiffer
Journal: Blood (2010)
Attention Deficit Hyperactivity Disorder (ADHD) and disordered eating behaviour: A systematic review and a framework for future research
Authors: Panagiota Kaisari, Colin T Dourish, Suzanne Higgs
Journal: Clinical Psychology Review (2017)

Preliminary findings suggest that Attention Deficit Hyperactivity Disorder (ADHD) may be associated with disordered eating behaviour, but whether there is sufficient evidence to suggest an association between ADHD and specific types of disordered eating behaviour is unclear. Furthermore, it is uncertain whether specific features associated with ADHD are differentially associated with disordered eating behaviour. A systematic review of seventy-five studies was conducted to evaluate the potential association between ADHD symptomatology and disordered eating behaviour and to provide an estimate of the strength of evidence for any association. Overall, a moderate strength of evidence exists for a positive association between ADHD and disordered eating and with specific types of disordered-eating behaviour, in particular, overeating behaviour. There is consistent evidence that impulsivity symptoms of ADHD are positively associated with overeating and bulimia nervosa and more limited evidence for an association between hyperactivity symptoms and restrictive eating in males but not females. Further research is required to assess the potential direction of the relationship between ADHD and disordered eating, the underlying mechanisms and the role of specific ADHD symptoms in the development and/or maintenance of disordered eating behaviour. We propose a framework that could be used to guide the design of future studies.
Abstract P5-14-05: Capecitabine in early breast cancer: A meta-analysis of randomized controlled trials
Authors: A Natori, J-L Ethier, E Amir, DW Cescon
Journal: Cancer Research (2017)

Abstract Background Capecitabine is an effective therapy for metastatic breast cancer. Its role in early breast cancer is uncertain due to conflicting data from randomized controlled trials (RCTs). Methods PubMed and major conference proceedings were searched to identify RCTs comparing standard chemotherapy (defined as cyclophosphamide/methotrexate/5-fluorouracil, anthracycline-based regimens or anthracycline/taxane combinations) with or without capecitabine in the neo-adjuvant or adjuvant setting. Hazard ratios (HR) for disease-free (DFS) and overall survival (OS), as well as odds ratios (ORs) for safety and tolerability were extracted or calculated and pooled in a meta-analysis. Subgroup analysis compared triple negative breast cancer (TNBC) to non-TNBC and whether capecitabine was given in addition to or in place of standard chemotherapy. Meta-regression was used to explore the influence of TNBC on OS. Results Eight studies comprising 9302 patients were included. In unselected patients, capecitabine did not influence DFS (HR 0.99, p=0.93) or OS (HR 0.90, p=0.36). There was a significant difference in DFS when capecitabine was given in addition to, compared to in place of standard treatment (HR 0.92 vs. 1.62, interaction p=0.002). Addition of capecitabine to standard chemotherapy was associated with significantly improved DFS in TNBC vs non-TNBC (HR 0.72 vs. 1.01, interaction p=0.02). Meta-regression confirmed this association with OS (R=-0.967, p=0.007). Capecitabine increased Grade 3/4 diarrhea (OR 2.33, p&amp;lt;0.001) and hand foot syndrome (OR 8.08, p&amp;lt;0.001), and resulted in more frequent treatment discontinuation (OR 3.80, p&amp;lt;0.001). Conclusion Adding capecitabine to standard chemotherapy appears to improve DFS and OS in TNBC, but increases adverse events in keeping with its known toxicity profile. Consideration of this treatment is warranted, especially in high-risk patients. Citation Format: Natori A, Ethier J-L, Amir E, Cescon DW. Capecitabine in early breast cancer: A meta-analysis of randomized controlled trials [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-14-05.
Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients
Authors: Anthony R. Mato, Brian T. Hill, Nicole Lamanna, Paul Barr, Chaitra S. Ujjani, Danielle M. Brander, Christina Howlett, Alan P Skarbnik, Bruce Cheson, Clive S Zent, Jeffrey J Pu, Pavel Kiselev, Spencer Henick Bachow, Allison M Winter, Allan-Louie Cruz, David F. Claxton, Catherine Daniel, Krista Isaack, Kaitlin H Kennard, Colleen Timlin, Molly Fanning, Melissa Yacur, Jakub Svoboda, Stephen J. Schuster, Chadi Nabhan
Journal: Blood (2016)
Pelvic Examinations in Nonpregnant Women
Authors: Jill Jin
Journal: JAMA (2017)

US Preventive Services Task Force; Kirsten Bibbins-Domingo, PhD, MD, MAS; David C. Grossman, MD, MPH; Susan J. Curry, PhD; Michael J. Barry, MD; Karina W. Davidson, PhD, MASc; Chyke A. Doubeni, MD, MPH; John W. Epling Jr, MD, MSEd; Francisco A. R. García, MD, MPH; Alex R. Kemper, MD, MPH, MS; Alex H. Krist, MD, MPH; Ann E. Kurth, PhD, RN, MSN, MPH; C. Seth Landefeld, MD; Carol M. Mangione, MD, MSPH; William R. Phillips, MD, MPH; Maureen G. Phipps, MD, MPH; Michael Silverstein, MD, MPH; Melissa Simon, MD, MPH; Albert L. Siu, MD, MSPH; Chien-Wen Tseng, MD, MPH, MSEE
Abstract P3-04-21: Androgen receptor in tamoxifen-resistant breast cancer is affected by SUMO
Authors: S Bahnassy, S Kumar, J Ren, G Frutiz, S Karami, T Bawa-Khalfe
Journal: Cancer Research (2017)

Abstract Resistance to tamoxifen is a major problem in treating women with estrogen receptor-positive (ERa+) breast cancer (BCa). Previous studies report elevated levels of the androgen receptor (AR) in tamoxifen-resistant (TamR) human mammary tumors. Inversely, in vitro overexpression of AR in ERa+-MCF-7 cells potentiates growth in the presence of tamoxifen. AR is a target for small ubiquitin like modifiers (SUMO) posttranslational modification (PTM). Prostate cancer (PCa) studies, show that SUMO-PTMs can have diverse effects on AR transcriptional activity, by modifying the AR itself or its co-regulators. SUMOylation regulates the AR's interaction with chromatin and modulates its function in a gene selective manner. Although SUMO-1 inhibited the AR transcriptional activity, SUMO-3 strongly enhanced the transactivation of AR in LNCaP cells but negatively affected the AR transcriptional activity in primary prostate epithelial cells. On the other hand, SUMO modifications and its subsequent effects on the AR in breast tumors and in particular TamR-BCa is unknown. Our objective is to understand how SUMO-PTMs affect AR activity in TamR-BCa. Others report that high Ubc9, a SUMO E2 conjugating enzyme, correlates with with aggressive phenotypes of BCa and that PIAS3, a SUMO E3 ligase, expression increases in breast tumors. Consistently, we now report that global SUMO2/3-conjugation is enhanced while the full-length SUMO protease SENP7 (SENP7L) is reduced in TamR-BCa cells. Collectively, these observations would suggest reduced SUMO dynamics in TamR-BCa as compared to tamoxifen-sensitive (TamS) BCa cells. Unlike PCa cells that favor unmodified over SUMOylated AR, we report that AR SUMOylation is potentiated in TamR-BCa cells. Functionally, SUMOylation of AR augments its chromatin binding and enhances its transcriptional activity. Our results suggest that the level of unmodified to SUMOylated AR is dramatically altered with onset of TamR and drives a functionally distinct population of AR in TamR versus TamS BCa. Consistently these biochemical reactions that define protein diversity could have a major impact on drug resistance in BCa. Citation Format: Bahnassy S, Kumar S, Ren J, Frutiz G, Karami S, Bawa-Khalfe T. Androgen receptor in tamoxifen-resistant breast cancer is affected by SUMO [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-04-21.
Where Is the Geriatrician?
Authors: Matteo Cesari, Riccardo Calvani, Emanuele Marzetti
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Keratinocyte Cancer Therapies Enter the Era of Targeted and Immunotherapy
Authors: Edit B. Olasz, Shahab Babakoohi, Zelmira Lazarova
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Impact of Bendamustine Pretreatment on Stem Cell Mobilization and Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
Authors: Wolfram Pönisch, Julia Wiesler, Ina Wagner, Sabine Leiblein, Elvira Edel, Haifa K. Al-Ali, Vladan Vucinic, Ute Hegenbart, Christiane Heiß, Dietger Niederwieser, Hartmut Goldschmidt
Journal: Blood (2011)
A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain
Authors: Deepitha Selvaraj, Vijayan Gangadharan, Christoph W. Michalski, Martina Kurejova, Sebastian Stösser, Kshitij Srivastava, Matthias Schweizerhof, Johannes Waltenberger, Napoleone Ferrara, Paul Heppenstall, Masabumi Shibuya, Hellmut G. Augustin, Rohini Kuner
Journal: Cancer Cell (2015)
EGFL7 Antagonizes NOTCH Signaling, Stimulates Blast Proliferation and Confers Poor Prognosis in Cytogenetically-Normal Acute Myeloid Leukemia (CN-AML)
Authors: Changxian Shen, Dimitrios Papaioannou, Betina Mcneil, Deedra Nicolet, Malith Karunasiri, Matthew Burke, Zitzer Nina, Gregory K. Behbehani, Hatice G Ozer, Selen Yilmaz, Guido Marcucci, Michael A. Caligiuri, Clara D. Bloomfield, Ramiro Garzon, Adrienne Dorrance
Journal: Blood (2016)
Health Outcomes and Costs of Rituximab in Combination with Cyclophosphamide, Vincristine and Prednisolone in the Treatment of Patients with Advanced Follicular Lymphoma in Portugal.
Authors: Paula Braga, Susana Carvalho, Marília Gomes, Lurdes Guerra, Paulo Lúcio, Herlander Marques, Filipa Negreiro, Catarina Pereira, Catarina Silva, Adriana Teixeira
Journal: Blood (2009)
Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes At US Transplant Centers: A Center for International Blood and Marrow Transplant Research (CIBMTR) Study
Authors: Mohamed L. Sorror, Brent R. Logan, Xiaochun Zhu, J. Douglas Rizzo, Kenneth R. Cooke, Philip L. McCarthy, Vincent T Ho, Barry Storer, Marcelo C Pasquini
Journal: Blood (2012)
A Single Institution Study of Allogeneic Hematopoietic Stem Cell Transplant for MDS and AML in Patients 60 Years of Age and Older: Impact of Disease Risk Index and Secondary Disease
Authors: Eva Gupta, Randi Hoffman, Thomas Colleen, William J Hogan, Mark R Litzow, Lisa Sproat, James M. Foran, Laura E. Finn, Vivek Roy
Journal: Blood (2015)
Abstract P3-17-05: Claudin-4 expression is associated with disease free survival in breast carcinoma in situ: Mean follow up of 8.2 years
Authors: GM Duarte, NR Almeida, F Tocchet, J Espinola, T Pinto, CT Barreto, GA Pinto, FA Soares, P Marshall, GR Paiva
Journal: Cancer Research (2017)

Abstract Introduction: Claudins are tight junction molecules that have been associated with breast cancer prognosis. The claudin-low intrinsic subtype of invasive carcinoma was recently described and associated with high grade carcinoma, low junction molecules expression and worse response to chemotherapy. However, it is not known whether the expression of claudins may provide clues as to carcinoma in situ prognosis. The aim of study was evaluate the association between claudin–4 expression and disease-free survival and histologic type of local recurrence in carcinoma in situ after longer follow up. Methods: A tissue microarray (TMA) block was constructed from 137 pure carcinoma in situ paraffin blocks sampled from patients treated from 1999 to 2009. The TMA was submitted to immunohistochemical staining for claudin-4. A claudin-4 score calculated based on percentage and intensity of expression, categorized samples as: claudin-4-low or claudin–4-high. Clinical data, treatment data, local recurrence data and survival of each patient were reanalyzed from medical records. Kaplan-Meier curves, log-rank and Wilcoxon tests were used to analyze disease-free survival; qui-square and Fisher test were employed to compare others variables; a significance level of 5 % was used. Results: Claudin-4 expression was evaluated in 86 samples, 88.4% were claudin-4-high and 11.6% claudin-4-low. Mean follow up was 8.2 years ( and local recurrence rate was 10.5 %. There was significant difference in the disease-free survival between claudin-4-high and claudin-4-low (4.9 x 1.9 respectively, p= 0.02); however there was no difference between both in histologic type of recurrence, invasive or in situ (p=0.44). Conclusion: In our samples, claudin-4-high expression in carcinoma in situ was more frequent than low expression. Our data showed that claudin-4-low expression had a worse prognosis in carcinomas in situ (inferior disease-free survival) but it was similar to claudin-4-high in histologic type of local recurrence. Citation Format: Duarte GM, Almeida NR, Tocchet F, Espinola J, Pinto T, Barreto CT, Pinto GA, Soares FA, Marshall P, Paiva GR. Claudin-4 expression is associated with disease free survival in breast carcinoma in situ: Mean follow up of 8.2 years [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-17-05.
Unrelated Umbilical Cord Blood Transplantation for Patients with Primary Immunodeficiency: A Report From the Registry of the Japan Cord Blood Bank Network
Authors: Tomohiro Morio, Daisuke Tomizawa, Yoshiko Atsuta, Tokiko Nagamura-Inoue, Koji Kato, Tadashi Ariga, Keisei Kawa, Kazutoshi Koike, Hisamichi Tauchi, Michiko Kajiwara, Toshirou Hara, Shunichi Kato
Journal: Blood (2010)
Abstract P1-11-07: Frozen section histology evaluation of surgical margins helps perform single step oncologically safe and cost-effective breast conservation surgery
Authors: G Agarwal, C Sonthineni, S Maylivahanan, G Chand, A Mishra, A Agarwal, AK Verma, SK Mishra, V Agrawal, N Krishnani, P Lal
Journal: Cancer Research (2017)

Abstract This abstract was withdrawn by the authors.
Abstract ES1-3: umor-stroma interactions in breast cancer progression
Authors: CM Isacke
Journal: Cancer Research (2017)

Abstract The interaction of tumor cells with stroma cells and stromal components not only promotes tumor progression and metastasis, but also influences tumor cell responses to chemotherapy, endocrine therapy and targeted agents. As a consequence, there is an urgent need to identify strategies to efficiently target these interaction pathways for the prevention or suppression of metastatic disease and to overcome treatment-resistant tumor progression in advanced breast cancer. This talk will focus on the tumor-stroma crosstalk pathways underpinning the striking heterogeneity between different breast cancers in their ability to recruit and activate a pro-tumorigenic stroma. In particular (a) the mechanisms involved in the activation of cancer-associated fibroblasts (CAFs), (b) the role of activated pericytes in promoting metastatic dissemination, and (c) the mechanisms by which a productive microenvironmental niche is initiated at metastatic sites. Citation Format: Isacke CM. umor-stroma interactions in breast cancer progression [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr ES1-3.